OverviewSuggest Edit
Dexcom is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. The company provides Dexcom Seven that can show a new glucose reading every five minutes for up to seven days of uninterrupted wear-time.
| Type | Public | |
| Founded | 1999 | |
| HQ | San Diego, CA, US | Map |
| Website | dexcom.com | |
| Employee Ratings | More | |
| Overall Culture | D | More |
Recent NewsAll News
- Worldwide Artificial Pancreas Device Systems Industry to 2026 - Key Players Include Beta Bionics, Dexcom and Insulet Among Others
- Despite A 23% Rise In A Month Dexcom Stock Will Likely See Higher Levels
- Can Dexcom Stock Rebound After The Recent 11% Drop?
- Heads Up Announces Full Integration With Dexcom for Enhanced Continuous Glucose Monitoring
Key People/Management at Dexcom
Kevin Sayer
Chairman, President & Chief Executive Officer
Quentin Blackford
Chief Financial Officer
Donald Abbey
EVP, Quality and Regulatory Affairs
Rick Doubleday
EVP, Chief Commercial Officer
Paul Flynn
EVP, Global Revenue
Andrew Balo
EVP, Regulatory Strategy, Clinical Affairs and Strategic Partnership Development
Dexcom Office Locations
Dexcom has offices in San Diego, Brunn am Gebirge, Burnaby, Mainz and in 2 other locations
San Diego, CA, US (HQ)
6340 Sequence Dr
Brunn am Gebirge, AT
Leopold-Gattringer-Straße 25
Burnaby, CA
501 Lougheed Hwy
Mainz, DE
Haifa-Allee 2
Horw, CH
Allmendstr. 18
Camberley, GB
Suite 2.12, Building 3, Watchmoor Park,
Dexcom Financials and Metrics
Dexcom Revenue
Dexcom's revenue was reported to be $1.93 b in FY, 2020
| USD | |
|---|---|
Net income (Q1, 2021) | 40.3m |
EBIT (Q1, 2021) | 45.9m |
Market capitalization (22-Jul-2021) | 43.2b |
Closing stock price (22-Jul-2021) | 450.9 |
Cash (31-Mar-2021) | 733.8m |
EV | 44.3b |
Dexcom's current market capitalization is $43.2 b.
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 184.4m | 242.5m | 266.7m | 280.5m | 336.4m | 396.3m | 405.1m | 451.8m | 500.9m | |
Cost of goods sold | 65.5m | 88.9m | 98.1m | 111.7m | 129.9m | 149.4m | 148.6m | 167.7m | 160.5m | 161.1m |
Gross profit | 118.9m | 153.6m | 168.6m | 168.8m | 206.5m | 246.9m | 256.5m | 284.1m | 340.4m | |
Gross profit Margin, % | 64% | 63% | 63% | 60% | 61% | 62% | 63% | 63% | 68% |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 420.4m | 300.2m | 367.4m | 1.3b | 709.2m | 395.6m | 584.6m | 530.0m | 673.5m | 733.8m |
Accounts Receivable | 123.9m | 162.0m | 169.8m | 204.7m | 217.3m | 234.9m | 300.7m | 296.5m | 370.0m | 443.4m |
Prepaid Expenses | 79.4m | |||||||||
Inventories | 51.6m | 46.2m | 55.2m | 101.1m | 117.9m | 120.4m | 141.9m | 165.3m | 200.7m | 289.7m |
Annual
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (24.2m) | 6.0m | 52.6m | (26.9m) | (37.4m) | 8.4m | 19.9m | 66.2m | 138.4m | 40.3m |
Depreciation and Amortization | 6.0m | 12.7m | 20.5m | 9.9m | 21.5m | 34.4m | 13.0m | 28.3m | 46.7m | 20.9m |
Inventories | (6.4m) | (1.0m) | (10.0m) | (30.4m) | (47.2m) | (49.7m) | (22.2m) | (45.5m) | (80.9m) | |
Accounts Payable | 2.2m | 32.9m | 50.2m | 25.5m | 53.9m | 78.2m | 5.3m | 56.8m | 126.6m |
| USD | FY, 2017 |
|---|---|
Revenue/Employee | 313.8k |
Debt/Equity | 0.8 x |
Debt/Assets | 0.4 x |
Financial Leverage | 2.2 x |
Dexcom Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| TypeZero Technologies Inc | August 22, 2018 | |
| Nintamed Handels GmbH | May 02, 2016 | |
| DexCapital LLC | ||
| DexCom Asia Pacific Operations PTE Ltd. | ||
| DexCom Canada Co | ||
| DexCom (Canada) Inc. | ||
| DexCom Deutschland GmbH | ||
| DexCom International Ltd. | ||
| DexCom Kommanditbolag | ||
| DexCom Operating Ltd. |
Dexcom Revenue Breakdown
Dexcom revenue breakdown by geographic segment: 21.3% from Outside of the United States and 78.7% from United States
Dexcom Cybersecurity Score
Dexcom Environment, Social & Governance (ESG) Ratings
Dexcom Online and Social Media Presence
7.47k Twitter followers
Dexcom has 7.47k Twitter Followers. The number of followers has increased 0.7% month over month and increased 0.8% quarter over quarter
Dexcom's Trends
Dexcom Company Culture
Overall Culture
D
61/100
CEO Rating
C+
67/100
Compensation
C
65/100
Diversity
D
57/100
Dexcom News and Updates
July 16, 2021
Worldwide Artificial Pancreas Device Systems Industry to 2026 - Key Players Include Beta Bionics, Dexcom and Insulet Among Others
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Artificial Pancreas Device Systems (APDS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global artificial pancreas device systems (APDS) market …
June 23, 2021
Despite A 23% Rise In A Month Dexcom Stock Will Likely See Higher Levels
Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the last twenty-one trading days. There were some positive developments for the company as well...
May 07, 2021
Can Dexcom Stock Rebound After The Recent 11% Drop?
While there have been rumors of AppleAAPL coming up with a CGM feature in its Apple Watch, the company hasn’t confirmed it yet. That said, if Apple does come up with this feature, it will surely take a toll on companies such as Dexcom and Abbott, that sell the wearable CGM devices, especially if..
March 09, 2021
Heads Up Announces Full Integration With Dexcom for Enhanced Continuous Glucose Monitoring
Enables Dexcom users to sync their glucose values onto a single, unified dashboard and share with any healthcare professional.
February 08, 2021
Can DexCom Stock Gain More After A 10% Rise In Last 5 Days?
The stock price of DexCom, best known for its continuous glucose monitoring systems, has risen by 10% over the last five trading days. Earlier in January, the company reported strong preliminary numbers for Q4, with an estimated top-line growth over 20% y-o-y. The company will report its Q4...
January 11, 2021
Teladoc Health and Dexcom Bring CGM Technology and Personalized Insights to People with Type 2 Diabetes at No Cost
New offering measures the impact of continuous glucose monitoring and real-time health recommendations for people with Type 2 diabetes New offering measures the impact of continuous glucose monitoring and real-time health recommendations for people with Type 2 diabetes
Dexcom Blogs
June 21, 2021
If I am replacing my smart device, what will I need to do?
FAQs Main Categories:
Dexcom G6 CGM System
FAQs Sub Categories:
Setting Up Your System
Language
US - English
LBL Number:
LBL021384 Rev001
If you are replacing your smart device and use the Dexcom G6, please review the following instructions. These steps are applicable for only the Dexco…
June 21, 2021
How do I create a Dependent Account?
FAQs Main Categories:
Follow App for Family & Friends
General
FAQs Sub Categories:
Using Your Dexcom CGM System
Setting Up Your System
Language
US - English
LBL Number:
LBL021379 Rev001
If you are a caregiver of a customer who is under 18 years old, you must create a dependent a…
May 10, 2021
Apple Watch SE
Device Family:
Apple Watch
Version:
Dexcom G6 app watchOS 7.3.2 ||Dexcom Follow app watchOS 7.3.2
Device Enabled:
May 10, 2021
Apple Watch Series 6
Device Family:
Apple Watch
Version:
Dexcom G6 app watchOS 7.3.2 ||Dexcom Follow app watchOS 7.3.2
Device Enabled:
April 07, 2021
Why am I being asked to update my phone’s operating system (OS) to continue getting Dexcom Follow app updates?
FAQs Main Categories:
Follow App for Family & Friends
FAQs Sub Categories:
Troubleshooting
Language
US - English
LBL Number:
LBL021023 Rev001
When an OS you’re using is no longer supported for your Dexcom Follow app, we will ask you to update your OS to continue getting app updates.…
April 07, 2021
Dexcom and Nick Jonas Unveil First-Ever Super Bowl Commercial
Language
US - English
Dexcom debuted their first ever Super Bowl commercial which calls for better care for people with diabetes who are still painfully pricking their fingers to measure their glucose levels.February2021Learn More
Dexcom Frequently Asked Questions
When was Dexcom founded?
Dexcom was founded in 1999.
Who are Dexcom key executives?
Dexcom's key executives are Kevin Sayer, Quentin Blackford and Donald Abbey.
How many employees does Dexcom have?
Dexcom has 3,900 employees.
What is Dexcom revenue?
Latest Dexcom annual revenue is $1.9 b.
What is Dexcom revenue per employee?
Latest Dexcom revenue per employee is $494 k.
Who are Dexcom competitors?
Competitors of Dexcom include LifeScan, Roche and Medtronic.
Where is Dexcom headquarters?
Dexcom headquarters is located at 6340 Sequence Dr, San Diego.
Where are Dexcom offices?
Dexcom has offices in San Diego, Brunn am Gebirge, Burnaby, Mainz and in 2 other locations.
How many offices does Dexcom have?
Dexcom has 6 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies